Pub Date : 2026-02-01DOI: 10.1016/j.jfma.2026.01.063
Yujie Weng, Kai Huang
{"title":"Comment on \"Retrospective study on biceps tendon rerouting and local grafting with coracohumeral ligament for massive rotator cuff repair in Taiwanese population\".","authors":"Yujie Weng, Kai Huang","doi":"10.1016/j.jfma.2026.01.063","DOIUrl":"https://doi.org/10.1016/j.jfma.2026.01.063","url":null,"abstract":"","PeriodicalId":17305,"journal":{"name":"Journal of the Formosan Medical Association","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146105972","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-01DOI: 10.1016/j.jfma.2026.01.029
Dianqing Li, Song Chen, Dong Wang, Lingqing Yuan
{"title":"Comment on \"Diagnostic value and fracture healing-preventing effect of upregulated microRNA-4534 in patients with osteoporotic fractures\".","authors":"Dianqing Li, Song Chen, Dong Wang, Lingqing Yuan","doi":"10.1016/j.jfma.2026.01.029","DOIUrl":"https://doi.org/10.1016/j.jfma.2026.01.029","url":null,"abstract":"","PeriodicalId":17305,"journal":{"name":"Journal of the Formosan Medical Association","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146105956","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-28DOI: 10.1016/j.jfma.2026.01.053
Yi-Yu Su, Pau-Chung Chen
{"title":"Response to the comment on \"Optimizing maternal weight gain to improve neonatal health: A nationwide birth cohort analysis in Taiwan\".","authors":"Yi-Yu Su, Pau-Chung Chen","doi":"10.1016/j.jfma.2026.01.053","DOIUrl":"https://doi.org/10.1016/j.jfma.2026.01.053","url":null,"abstract":"","PeriodicalId":17305,"journal":{"name":"Journal of the Formosan Medical Association","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2026-01-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146086300","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-28DOI: 10.1016/j.jfma.2026.01.052
{"title":"Response to the Letter \"Beyond one size fits all: Towards BMI-specific gestational weight gain guidelines for Asian women\".","authors":"","doi":"10.1016/j.jfma.2026.01.052","DOIUrl":"https://doi.org/10.1016/j.jfma.2026.01.052","url":null,"abstract":"","PeriodicalId":17305,"journal":{"name":"Journal of the Formosan Medical Association","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2026-01-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146086313","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-26DOI: 10.1016/j.jfma.2026.01.035
Pei-Hao Chen, Jung-Lung Hsu
Alzheimer's disease (AD) is a major global health burden whose diagnosis has shifted from syndromic assessment to a biologically grounded framework anchored in biomarkers. This review traces the evolution of diagnostic criteria, highlights the complementary roles of amyloid positron emission tomography (PET), tau PET, and fluid biomarkers, and discusses the growing clinical utility of blood-based tests-especially phosphorylated tau assays-with performance approaching that of cerebrospinal fluid (CSF) and PET measures. We also examine how the advent of disease-modifying anti-amyloid therapies has accelerated biomarker-guided pathways for patient selection, prognosis, and monitoring. Finally, we outline ethical issues surrounding preclinical diagnosis and survey future directions, including artificial intelligence (AI), neuroinflammation and synaptic markers, and personalized therapies. Collectively, these developments represent progress toward a precision-medicine model for AD, though major barriers to equitable and clinically meaningful implementation remain.
{"title":"Alzheimer's disease diagnosis: An update and review of biomarkers, positron emission tomography, and emerging therapies.","authors":"Pei-Hao Chen, Jung-Lung Hsu","doi":"10.1016/j.jfma.2026.01.035","DOIUrl":"https://doi.org/10.1016/j.jfma.2026.01.035","url":null,"abstract":"<p><p>Alzheimer's disease (AD) is a major global health burden whose diagnosis has shifted from syndromic assessment to a biologically grounded framework anchored in biomarkers. This review traces the evolution of diagnostic criteria, highlights the complementary roles of amyloid positron emission tomography (PET), tau PET, and fluid biomarkers, and discusses the growing clinical utility of blood-based tests-especially phosphorylated tau assays-with performance approaching that of cerebrospinal fluid (CSF) and PET measures. We also examine how the advent of disease-modifying anti-amyloid therapies has accelerated biomarker-guided pathways for patient selection, prognosis, and monitoring. Finally, we outline ethical issues surrounding preclinical diagnosis and survey future directions, including artificial intelligence (AI), neuroinflammation and synaptic markers, and personalized therapies. Collectively, these developments represent progress toward a precision-medicine model for AD, though major barriers to equitable and clinically meaningful implementation remain.</p>","PeriodicalId":17305,"journal":{"name":"Journal of the Formosan Medical Association","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2026-01-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146064361","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Background/objective: Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy with limited later-line therapeutic options. This retrospective study aimed to evaluate the efficacy and safety of platinum-based chemotherapy as third-line treatment for metastatic PDAC.
Methods: We analyzed 102 patients who received third-line systemic treatment for PDAC between 2018 and 2023 across five medical centers in Taiwan. All patients had previously received first-line gemcitabine-based therapy and second-line nanoliposomal irinotecan with 5-fluorouracil and leucovorin. Overall, one group (N = 40) received platinum-based regimens, whereas the other group (N = 62) received non-platinum-based treatments. Survival outcomes and treatment-related toxicities were compared between the groups.
Results: The median overall survival (OS) duration was 5.8 months (95 % CI, 3.3-8.3) for the platinum group and 4.3 months (95 % CI, 3.5-5.0) for the non-platinum group, without a statistically significant difference (HR, 0.74, 95 % CI: 0.46-1.18, p = 0.21). The median time-to-treatment failure was 2.4 months (95 % CI, 1.6-3.2) and 2.1 months (95 % CI, 1.3-2.9), respectively (HR, 0.85, 95 % CI: 0.57-1.28, p = 0.44). Subgroup analyses suggested that younger age and no history of pancreatectomy tended to associate with better OS following platinum-based treatment. However, the platinum group experienced a higher incidence aspartate aminotransferase elevation (13 % vs. 2 %, p = 0.033) and increased creatinine (13 % vs. 2 %, p = 0.033) levels than the non-platinum group.
Conclusions: This study showed that a platinum-based third-line chemotherapy regimen for patients with metastatic PDAC did not confer a significant survival advantage over non-platinum-based regimens. Platinum-based regimens are associated with modestly increased treatment-related toxicities, thus potentially limiting their tolerability in these heavily pretreated patients.
背景/目的：胰腺导管腺癌（PDAC）是一种晚期治疗选择有限的侵袭性恶性肿瘤。本回顾性研究旨在评估铂类化疗作为转移性PDAC三线治疗的有效性和安全性。方法：我们分析了台湾五家医疗中心2018年至2023年间接受PDAC三线全身治疗的102例患者。所有患者先前均接受过一线吉西他滨治疗和二线纳米脂质体伊立替康联合5-氟尿嘧啶和亚叶酸钙。总体而言，一组（N = 40）接受以铂为基础的治疗方案，而另一组（N = 62）接受非铂为基础的治疗。比较两组患者的生存结果和治疗相关的毒性。结果：铂组的中位总生存期为5.8个月（95% CI, 3.3-8.3），非铂组的中位总生存期为4.3个月（95% CI, 3.5-5.0），差异无统计学意义（HR, 0.74, 95% CI: 0.46-1.18, p = 0.21）。治疗失败的中位时间分别为2.4个月（95% CI, 1.6-3.2）和2.1个月（95% CI, 1.3-2.9） （HR, 0.85, 95% CI: 0.57-1.28, p = 0.44）。亚组分析表明，年龄较小且无胰腺切除术史的患者在铂基治疗后的OS较好。然而，与非铂组相比，铂组的天冬氨酸转氨酶升高（13% vs. 2%, p = 0.033）和肌酐升高（13% vs. 2%, p = 0.033）的发生率更高。结论：这项研究表明，对于转移性PDAC患者，以铂为基础的三线化疗方案并没有比非铂为基础的方案带来显著的生存优势。以铂为基础的方案与治疗相关毒性的适度增加相关，因此可能限制了这些大量预处理患者的耐受性。
{"title":"Third-line platinum-based chemotherapy for patients with metastatic pancreatic ductal adenocarcinoma.","authors":"Chi-Chen Lan, Chieh-Ying Chang, Tai-Jan Chiu, Chia-Yen Hung, Kun-Yun Yeh, Chang-Hsien Lu, Yen-Yang Chen, Jen-Shi Chen, Yu-Shin Hung, Wen-Chi Chou","doi":"10.1016/j.jfma.2026.01.057","DOIUrl":"https://doi.org/10.1016/j.jfma.2026.01.057","url":null,"abstract":"<p><strong>Background/objective: </strong>Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy with limited later-line therapeutic options. This retrospective study aimed to evaluate the efficacy and safety of platinum-based chemotherapy as third-line treatment for metastatic PDAC.</p><p><strong>Methods: </strong>We analyzed 102 patients who received third-line systemic treatment for PDAC between 2018 and 2023 across five medical centers in Taiwan. All patients had previously received first-line gemcitabine-based therapy and second-line nanoliposomal irinotecan with 5-fluorouracil and leucovorin. Overall, one group (N = 40) received platinum-based regimens, whereas the other group (N = 62) received non-platinum-based treatments. Survival outcomes and treatment-related toxicities were compared between the groups.</p><p><strong>Results: </strong>The median overall survival (OS) duration was 5.8 months (95 % CI, 3.3-8.3) for the platinum group and 4.3 months (95 % CI, 3.5-5.0) for the non-platinum group, without a statistically significant difference (HR, 0.74, 95 % CI: 0.46-1.18, p = 0.21). The median time-to-treatment failure was 2.4 months (95 % CI, 1.6-3.2) and 2.1 months (95 % CI, 1.3-2.9), respectively (HR, 0.85, 95 % CI: 0.57-1.28, p = 0.44). Subgroup analyses suggested that younger age and no history of pancreatectomy tended to associate with better OS following platinum-based treatment. However, the platinum group experienced a higher incidence aspartate aminotransferase elevation (13 % vs. 2 %, p = 0.033) and increased creatinine (13 % vs. 2 %, p = 0.033) levels than the non-platinum group.</p><p><strong>Conclusions: </strong>This study showed that a platinum-based third-line chemotherapy regimen for patients with metastatic PDAC did not confer a significant survival advantage over non-platinum-based regimens. Platinum-based regimens are associated with modestly increased treatment-related toxicities, thus potentially limiting their tolerability in these heavily pretreated patients.</p>","PeriodicalId":17305,"journal":{"name":"Journal of the Formosan Medical Association","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2026-01-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146064357","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-24DOI: 10.1016/j.jfma.2026.01.054
Shuai Huang, Di Wu, Xiaofeng Cai
{"title":"Comment on \"The predict value of lymph node status pre-operation by ultrasound, mammography and MRI in early breast cancer\".","authors":"Shuai Huang, Di Wu, Xiaofeng Cai","doi":"10.1016/j.jfma.2026.01.054","DOIUrl":"https://doi.org/10.1016/j.jfma.2026.01.054","url":null,"abstract":"","PeriodicalId":17305,"journal":{"name":"Journal of the Formosan Medical Association","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2026-01-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146046795","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-24DOI: 10.1016/j.jfma.2026.01.028
Hong-Mei Qiu, Chao Liu, Guang Qin
{"title":"A critical appraisal of intratumoral microbiota as key regulators in primary liver cancer subtypes and recurrence.","authors":"Hong-Mei Qiu, Chao Liu, Guang Qin","doi":"10.1016/j.jfma.2026.01.028","DOIUrl":"https://doi.org/10.1016/j.jfma.2026.01.028","url":null,"abstract":"","PeriodicalId":17305,"journal":{"name":"Journal of the Formosan Medical Association","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2026-01-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146046710","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-24DOI: 10.1016/j.jfma.2026.01.044
Pin-Shuan Chen, Chung-Hua Hsu, Yu-Hwei Tseng
{"title":"Author response to Ye: Building the workforce.","authors":"Pin-Shuan Chen, Chung-Hua Hsu, Yu-Hwei Tseng","doi":"10.1016/j.jfma.2026.01.044","DOIUrl":"https://doi.org/10.1016/j.jfma.2026.01.044","url":null,"abstract":"","PeriodicalId":17305,"journal":{"name":"Journal of the Formosan Medical Association","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2026-01-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146046749","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-24DOI: 10.1016/j.jfma.2026.01.050
Pin-Shuan Chen, Chung-Hua Hsu, Yu-Hwei Tseng
{"title":"Author response to comment.","authors":"Pin-Shuan Chen, Chung-Hua Hsu, Yu-Hwei Tseng","doi":"10.1016/j.jfma.2026.01.050","DOIUrl":"https://doi.org/10.1016/j.jfma.2026.01.050","url":null,"abstract":"","PeriodicalId":17305,"journal":{"name":"Journal of the Formosan Medical Association","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2026-01-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146046779","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号